Aerobic exercise training and weight loss (AEX+WL) improves insulin sensitivity in overweight adults; however, the underlying pathways are incompletely understood. Fetuin-A, a hepatokine that inhibits insulin signaling, may be involved in the salutary effects of AEX+WL. Therefore, we examined the effects of 6-month AEX+WL on plasma fetuin-A levels (36–48 hours after the last bout of exercise), aerobic capacity (VO2max), body composition, glucose tolerance, and insulin sensitivity (M) in 16 sedentary, overweight-obese older men (age = 60 ± 2 years, BMI = 31 ± 1 kg/m²) with no history of cardiovascular disease or diabetes. At baseline, fetuin-A levels correlated directly with adiposity and had a borderline inverse correlation with M. After AEX+WL, body weight decreased by ~10 kg, while both VO2max and M increased by 16% (P < 0.005 for all). Contrary to our hypothesis, plasma fetuin-A levels increased after AEX+WL (1.16 ± 0.10 g/L versus 1.70 ± 0.19 g/L, P = 0.006). This increase was unrelated to changes in body composition or glucose metabolism, but directly correlated with changes in VO2max (r = 0.57, P < 0.05). Thus, in overweight-to-obese older men, AEX+WL appears to increase plasma fetuin-A levels. Although not associated with improvements in insulin sensitivity, this increase in fetuin-A was related to improvements in aerobic capacity and could be representative of the cardioprotective effects of AEX+WL in older men.

1. Introduction

Obesity is a growing problem in the United States where approximately two-thirds of adults aged 20 years or older are overweight or obese (BMI ≥ 25) [1]. Linked to increased weight is metabolic dysfunction (e.g., type 2 diabetes and dyslipidemia) that may, in part, be attributable to cytokines and hepatokines such as fetuin-A (α2-Heremans-Schmid glycoprotein). Fetuin-A is an abundant serum protein, almost exclusively expressed and secreted by hepatocytes and adipocytes, whose levels are upregulated in hepatic steatosis and metabolic disorders [2, 3]. In particular, fetuin-A has been shown to bind the insulin receptor and inhibit autophosphorylation of tyrosine kinase to decrease insulin signaling in cell culture models [4, 5]. Fetuin-A also has been implicated in promoting insulin resistance through proinflammatory effects in human monocytes and adipocytes, as well as reducing expression of adiponectin in human adipocytes in vitro [6]. In a number of cross-sectional and observational studies in humans, fetuin-A has been linked to insulin resistance and diabetes, often independently of body composition and other cardiovascular disease risk factors [2, 7–9]. Similarly, a relationship between circulating fetuin-A levels and CVD risk has been demonstrated in older adults [9, 10]; however, it is noteworthy that there is a direct relationship between fetuin-A levels and CVD risk in individuals with type 2 diabetes, while this relationship is inverse in older adults without type 2 diabetes [9].

Subcutaneous and visceral adipose tissue secretes fetuin-A, and in animal models, circulating levels of fetuin-A vary directly with percent fat mass when fat mass is manipulated by experimental conditions such as diet-induced obesity,
exercise training, and weight loss induced by activity-based anorexia [11]. Furthermore, weight loss has been demonstrated to reduce circulating fetuin-A levels in humans [12, 13]. To date, few studies have addressed the effects of aerobic exercise training (AEX) with or without weight loss (WL) on fetuin-A and its relationship to metabolic outcomes, and the results of these studies have been somewhat contradictory. Six weeks of AEX with modest changes in body composition had no effect on serum fetuin-A levels in obese older women [14]; however, 12 weeks of AEX with significant WL did reduce plasma fetuin-A levels in a study of obese older men and women [15]. It is unclear whether these discrepant findings are attributable to differences in the duration of the intervention, weight loss, or the sex of the participants; however, there is some evidence that relationships between fetuin-A levels and metabolic outcomes differ between men and women [16].

To deepen our understanding of the relationship between fetuin-A and cardiometabolic outcomes, we examined the effects of longer duration AEX+WL in a group of overweight-to-obese, older men, without the potential confounding effect of sex differences. We tested the hypothesis that six-month AEX+WL would reduce circulating fetuin-A levels and that this reduction would be associated with improvements in insulin sensitivity.

2. Materials and Methods

Sedentary, overweight, or obese men 50–75 years of age without a history of either cardiovascular disease or diabetes were recruited from the greater Baltimore-Washington D.C. region for participation in exercise and weight loss studies. Data from sixteen men are reported herein; subject characteristics and certain metabolic data from nine of these subjects were previously reported as part of another study [17]. Participants were screened by medical history, physical examination, and treadmill exercise tests. Exclusion criteria included (i) cancer, as well as hematological, pulmonary, renal, or thyroid disease; (ii) medications such as beta-blockers, steroids, statins, or medications normally prescribed for diabetes; and (iii) poorly controlled hypertension, dyslipidemia, or anemia. All subjects were nonsmokers, sedentary (no moderate or vigorous exercise ≥20 minutes on 2 or more days/week), and weight stable (no recent weight change of more than 2 kg) and reported consuming no more than two alcoholic drinks per day. All study procedures were approved by the Institutional Review Board at the University of Maryland School of Medicine, and all participants provided written informed consent.

2.1. Study Protocol. Prior to research testing, all subjects received instruction on maintaining a weight-stable, therapeutic lifestyle changes diet by a registered dietitian 1 day per week for 6–8 weeks. All subjects were weight-stable (±2%) for at least 2 weeks prior to research testing and were provided an isocaloric diet for 2 days before testing to control nutrient intake, as previously described [18]. Subjects were also asked to refrain from any moderate-to-vigorous physical exercise during this 2-day period. Similar conditions were maintained for postintervention testing; however, testing was performed 36–48 hours after the last bout of exercise.

2.1.1. Maximal Oxygen Consumption (VO₂max). VO₂max was measured using indirect calorimetry (Quark, Cosmed, Chicago, IL, USA) during a graded exercise test on a motorized treadmill as previously described [18, 19]. Briefly, subjects walked at a constant velocity throughout the protocol; grade was initially set to 0% and increased every 2 minutes thereafter to maximal effort. VO₂max was defined as the highest oxygen consumption value obtained for a full 30-second increment. All subjects attained VO₂max as evidenced by standard physiological criteria (respiratory exchange ratio > 1.10 or a plateau in VO₂ with an increase in workload).

2.1.2. Body Mass Index and Body Composition. Body weight was measured to the nearest 0.1 kg with an electronic scale, and standing height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. Body mass index (BMI) was calculated by dividing body weight (kilograms) by height (meters squared). Body composition (fat mass, lean mass, and percent body fat) was determined by dual-energy X-ray absorptiometry (Prodigy, Lunar Radiation Corp., Madison, WI, USA).

2.1.3. Oral Glucose Tolerance Test. All subjects underwent a 2-hour oral glucose tolerance test (OGTT) after a 12-hour overnight fast, as previously described [18]. A catheter was placed in an antecubital vein, and blood samples were drawn before and every 30 minutes after the ingestion of a 75 g glucose solution for 2 hours. Blood samples were centrifuged, and plasma was separated and stored at −80°C until analysis. Plasma glucose levels were analyzed with a glucose analyzer (YSI 2300 STAT Plus, YSI, Yellow Springs, OH, USA). Glucose area under the curve (G\textsubscript{AUC}) was calculated using the trapezoidal method.

2.1.4. Hyperinsulinemic-Euglycemic Clamp. Insulin-stimulated glucose uptake (M) was measured as an index of insulin sensitivity. Subjects were provided with all meals for the 2 days preceding the clamp to control nutrient intake. After a 12-hour overnight fast, subjects underwent hyperinsulinemic-euglycemic clamp [20, 21] as performed in our laboratory [22]. Insulin was infused at a rate of 80 mU/m²/min, and M is reported in mg of glucose infused per kilogram of body weight per minute (mg/kg/min) or micromoles of glucose infused per kilogram of fat-free mass per minute (μmol/kgFFM/min). Plasma glucose levels were analyzed at 5-minute intervals using the glucose oxidase method (Beckman Instruments, Fullerton, CA). Plasma insulin levels were determined by radioimmunoassay (EMD Millipore, St. Charles, MO).

2.1.5. Plasma Fetuin-A Levels. Fetuin-A concentration in plasma was measured by enzyme-linked immunosorbent assays (ELISA) (Epitope Diagnostics, San Diego, CA) according to the manufacturer’s instructions. Each sample was analyzed in triplicate, with the mean of three values used for statistical analyses; the intra-assay coefficient of variation
Table 1: Subject characteristics and responses to aerobic exercise training with weight loss (AEX+WL).

|                      | Baseline      | 6-month AEX+WL | P value |
|----------------------|---------------|----------------|---------|
| Age                  | 60 ± 2        | —              | —       |
| Weight (kg)          | 99.0 ± 3.5    | 89.5 ± 3.2     | <0.001  |
| BMI (kg/m²)          | 30.7 ± 0.8    | 28.2 ± 0.8     | <0.001  |
| Body fat (%)         | 31.9 ± 1.0    | 27.4 ± 1.4     | <0.001  |
| Fat mass (kg)        | 31.7 ± 1.9    | 25.4 ± 2.1     | <0.001  |
| Fat-free mass (kg)   | 65.2 ± 2.0    | 64.2 ± 2.0     | 0.10    |
| VO₂max (L/min)       | 2.46 ± 0.14   | 2.86 ± 0.17    | 0.003   |
| Fasting plasma glucose (mmol/L) | 5.27 ± 0.09 | 5.21 ± 0.14 | 0.60    |
| 2 hr postprandial glucose (mmol/L) | 7.67 ± 0.57 | 6.63 ± 0.59 | 0.15    |
| Glucose AUC (mmol/L/120 min) | 976 ± 49     | 901 ± 51       | 0.03    |
| M (mg/kg/min)        | 5.23 ± 0.46   | 6.77 ± 0.55    | <0.001  |
| M (μmol/kgFFM/min)   | 43.8 ± 4.1    | 50.8 ± 3.8     | 0.004   |
| Total cholesterol (mg/dL) | 4.46 ± 0.22   | 4.27 ± 0.23    | 0.25    |
| HDL-C (mg/dL)        | 0.99 ± 0.05   | 1.11 ± 0.06    | 0.009   |
| LDL-C (mg/dL)        | 2.89 ± 0.18   | 2.67 ± 0.19    | 0.15    |
| Triglycerides (mg/dL) | 1.27 ± 0.11   | 1.15 ± 0.14    | 0.32    |
| Systolic BP (mmHg)   | 122 ± 3       | 114 ± 2        | 0.03    |
| Diastolic BP (mmHg)  | 75 ± 1        | 70 ± 2         | 0.02    |

Data are means ± SEM. BMI: body mass index; VO₂max: maximal oxygen consumption; AUC: area under the curve; M: insulin-stimulated glucose uptake; FFM: fat-free mass; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; BP: blood pressure.

was less than 8%. All samples from each subject (before and after AEX+WL) were analyzed on the same plate.

2.1.6. AEX+WL. After the completion of baseline testing, subjects underwent 6 months of AEX training at the Baltimore VA GRECC exercise facility supervised by trained exercise physiologists. AEX training began at a volume of 3 sessions/week of 20 minutes at 50% of VO₂max and gradually increased to 3 sessions/week of 45 minutes at 60–70% of VO₂max, a level maintained for >4 months. During this 6-month period, subjects also met weekly with a registered dietician and were counseled to restrict their caloric intake by 500 kcal/day to achieve >5% weight loss. At the end of the 6-month intervention, the testing battery was repeated under identical conditions.

2.1.7. Statistical Analysis. Data are presented as means ± SEM. All statistical analyses were performed using IBM SPSS v22 (IBM, Armonk, NY, USA). Paired t-tests were used to test for differences in outcome variables before and after AEX+WL. Bivariate correlation analyses and regression analyses were used to test for associations between fetuin-A levels and metabolic variables. A type I error rate of α = 0.05 was selected, and two-tailed probabilities are reported for all analyses.

3. Results

Sixteen participants (mean age = 60 ± 2 years, BMI = 31 ± 1 kg/m²) completed the six-month AEX+WL intervention, and their metabolic data are shown in Table 1. At baseline, fetuin-A levels directly correlated with percent fat (r = 0.59, P = 0.016) and with BMI (r = 0.43, P = 0.01) and tended to correlate inversely with M expressed in mL/kg/min (r = −0.45, P = 0.08), but not with M expressed in μmol/kgFFM/min (r = −0.35, P = 0.18). Fetuin-A levels did not correlate with measures of glucose tolerance (fasting glucose, 120 minute glucose, or GₐₑᵤₙC), nor with VO₂max.

The AEX+WL intervention resulted in significant 10% losses in weight (−9.5 ± 1.7 kg, P < 0.001) and body fat (−4.5 ± 0.8%, P < 0.001), as well as a 16% improvement in VO₂max (+0.40 ± 0.11 L/min, P = 0.003). These changes in body composition and aerobic capacity were accompanied by improvements in cardiometabolic measures, including 6% decreases in systolic and diastolic blood pressure (P < 0.05), a 12% increase in high-density lipoprotein cholesterol (HDLC; P < 0.05), an 8% decrease in GₐₑᵤₙC, and a 16% increase in M (μmol/kgFFM/min, P < 0.001).

Contrary to our hypothesis, fetuin-A levels increased 47% after AEX+WL (Figure 1(a), P = 0.006). In addition, despite the correlation between percent fat and fetuin-A at baseline, the changes in fetuin-A level were unrelated to changes in weight or body composition (r = 0.06–0.14, P > 0.63). The AEX+WL induced increases in fetuin-A level correlated only with those in aerobic capacity expressed as VO₂max in L/min (Figure 1(b), r = 0.57, P = 0.027), and neither with changes in M nor 120-minute postprandial glucose (r = −0.26 to −0.37, P > 0.18). Inclusion of the change in weight or fat mass did not affect the association of the changes in fetuin-A levels with VO₂max (VO₂max partial r = 0.59, P = 0.036).

4. Discussion

Circulating levels of fetuin-A previously have been associated with diabetes risk and hypothesized to play a role in the
compared with baseline, $P<0.006$. This increase in fetuin-A was significantly following AEX+WL, in direct correlation with the improvements in VO2max. The changes in fetuin-A level directly correlated with changes in VO2max ($r=0.57$, $P=0.027$).

Figure 1: (a) Plasma fetuin-A levels at baseline and after aerobic exercise training and weight loss (AEX+WL). *Significant difference compared with baseline, $P=0.006$. (b) Scatterplot depicting the relationship between AEX+WL-induced changes in VO2max and circulating fetuin-A levels. The changes in fetuin-A level directly correlated with changes in VO2max ($r=0.57$, $P=0.027$).

development of insulin resistance in overweight and obese people. Therefore, we assessed the effects of six-month AEX +WL on circulating fetuin-A levels as a potential mediator of AEX+WL-induced improvements in insulin sensitivity and cardiometabolic outcomes. As expected, participants lost weight and increased VO2max, while also realizing improvements in insulin sensitivity, blood pressure, and lipoprotein-lipid profiles after AEX+WL. However, contrary to our hypothesis, plasma fetuin-A levels increased significantly following AEX+WL, in direct correlation with the improvements in VO2max. This increase in fetuin-A was unrelated to the improvement in insulin sensitivity, a finding inconsistent with a direct contribution of fetuin-A to improvements in glucose metabolism after AEX+WL in older men.

In rodent models, fetuin-A has been shown to bind the insulin receptor where it inhibits the autophosphorylation of tyrosine kinase to decrease insulin signaling [4], and in murine skeletal muscle, fetuin-A may similarly inhibit AS160 phosphorylation [23]. Fetuin-A also has been implicated to promote insulin resistance through proinflammatory effects, including augmenting cytokine expression and reducing that of adiponectin [6]. Despite subsequent findings of associations between fetuin-A levels, insulin resistance, and the development of diabetes in humans [7, 24], few studies have assessed the effects of AEX or WL interventions on circulating fetuin-A levels and relationships to metabolic outcomes. In morbidly obese women, bariatric surgery resulting in 35% weight loss reduced fetuin-A levels, which correlated with improvements in glucose tolerance [12]. Another study reported more modest decreases ($<5\%$) in fetuin-A levels after dietary WL [13]. However, given the differences in WL and lack of AEX intervention, it is difficult to directly compare these findings with the present study. In one study of WL with increases in physical activity, fetuin-A levels decreased in a subset of participants, but this appeared dependent on a reduction in liver fat content [25].

In another study of obese older men and women, 12 weeks of AEX and a degree of WL similar to the present study significantly reduced plasma fetuin-A levels [15]. This reduction in fetuin-A levels was associated with both body composition and metabolic improvements; however, similar to the present report, the change in fetuin-A levels did not correlate with the change in insulin-stimulated glucose uptake during a glucose clamp [15]. Recently, Lee et al. have reported that circulating levels of fetuin-A decreased $\sim 11\%$ in middle-aged men in response to a 12-week program of combined endurance and strength training; these changes in circulating fetuin-A interacted with those in free fatty acids to predict some of the improvements in insulin sensitivity [26]. Other studies have reported equivocal results in response to diet and exercise interventions. Schultes et al. found no change in serum fetuin-A levels in obese, premenopausal women after a 6-week AEX intervention that induced only modest ($<1\%$) changes in body fat [14]. Similarly, Yang et al. found no change in serum fetuin-A levels in middle-aged women after a three-month AEX and strength training intervention that resulted in $\sim 5\%$ WL [27]. Given the discrepant findings among studies of different sex and age groups, different methods of WL (with or without AEX), and different timing of fetuin-A measurement (e.g., with 24 hours versus 36–48 hours after the last bout of AEX in the present study), a more comprehensive study of changes in fetuin-A levels as a function of lifestyle interventions appears necessary.

It also remains possible that the observed association between fetuin-A levels and insulin resistance is not causal in humans. For example, a large study assessing variation in the gene encoding fetuin-A found that common genetic variants were strongly associated with plasma fetuin-A level, but there was no relationship with risk for type 2 diabetes or plasma glucose levels [28]. Our finding of improvements in insulin sensitivity despite increases in plasma fetuin-A levels
is inconsistent with fetuin-A playing a major causal role in insulin resistance in humans. Nonetheless, while we did not find associations with insulin sensitivity, it is possible that higher fetuin-A levels seen after AEX+WL could play a protective role in preventing ectopic calcifications, as improved vascular health and reduced cardiovascular disease risk are known benefits of exercise, and fetuin-A levels have been shown to be inversely associated with the presence of calcified plaques [29, 30]. In fact, fetuin-A is highly effective in the formation and stabilization of protein-mineral colloids and acts as a carrier for both calcium and phosphate [31]. With regard to this issue too, somewhat discordant results have previously been reported, with direct correlations between fetuin-A levels and carotid artery intima-media thickness, as well as inverse correlations with coronary artery calcification and global measures of atherosclerosis [30, 32–35]. Furthermore, correlations with coronary artery calcification and global measures of atherosclerosis [30, 32–35]. With regard to this issue too, somewhat discordant results have previously been reported, with direct correlations between fetuin-A levels and carotid artery intima-media thickness, as well as inverse correlations with coronary artery calcification and global measures of atherosclerosis [30, 32–35].

5. Conclusions

We report an increase in plasma fetuin-A levels following a 6-month AEX+WL protocol in overweight-to-obese older men that correlates with the increase in VO_{2\text{max}}, although not with other observed improvements in insulin sensitivity. Thus, in overweight-obese older men, fetuin-A does not appear to play a major role in these metabolic improvements induced by AEX+WL, although the increase in fetuin-A could potentially confer benefit with regard to CVD risk.

Conflicts of Interest

The authors have no conflict of interest to declare.

Acknowledgments

The authors’ appreciation is extended to the subjects who participated in this study and to Lyndon J. Joseph, Ph.D., for his contributions to the study. This research was supported by a VA Advanced Research Career Development Award (Jacob B. Blumenthal), a VA Merit Review Award (Alice S. Ryan), NIH K01-AG-021457 (Lyndon J. Joseph), a Paul B. Beeson Patient-Oriented Research Career Development Award in Aging (NIH K23-AG040775 and AFAR, Steven J. Prior), a VA Career Development Award (Steven J. Prior), a VA Senior Research Career Scientist Award (Alice S. Ryan), the University of Maryland Claude D. Pepper Center (NIH P30-AG028747), the Mid-Atlantic Nutrition Obesity Research Center (P30-DK072488), and the Baltimore Veterans Affairs Medical Center Geriatric Research, Education and Clinical Center (GRECC).

References

[1] C. L. Ogden, M. D. Carroll, B. K. Kit, and K. M. Flegal, “Prevalence of childhood and adult obesity in the United States, 2011–2012,” JAMA, vol. 311, pp. 806–814, 2014.
[2] N. Stefan, A. Fritsche, C. Weikert et al., “Plasma fetuin-A levels and the risk of type 2 diabetes,” Diabetes, vol. 57, pp. 2762–2767, 2008.
[3] J. H. Ix, M. G. Shlipak, V. M. Brandenburg, S. Ali, M. Ketteler, and M. A. Whooley, “Association between human fetuin-A and the metabolic syndrome: data from the heart and soul study,” Circulation, vol. 113, pp. 1760–1767, 2006.
[4] S. T. Mathews, N. Chellam, P. R. Srinivas et al., “Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor,” Molecular and Cellular Endocrinology, vol. 164, pp. 87–98, 2000.
[5] P. R. Srinivas, A. S. Wagner, L. V. Reddy et al., “Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level,” Molecular Endocrinology, vol. 7, pp. 1445–1455, 1993.
[6] A. M. Hennige, H. Stäger, C. Wicke et al., “Fetuin-A induces cytokine expression and suppresses adiponectin production,” PloS One, vol. 3, article e1765, 2008.
A. Obuchi, H. Adachi, M. Enomoto et al., “Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study,” Circulation, vol. 125, pp. 2316–2322, 2012.

J. H. Ix, C. L. Wassel, A. M. Kanaya et al., “Fetuin-A and incident diabetes mellitus in older persons,” JAMA, vol. 300, pp. 182–188, 2008.

M. K. Jensen, T. M. Bartz, K. J. Mukamal et al., “Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: the cardiovascular health study,” Diabetes Care, vol. 36, pp. 1222–1228, 2013.

P. Lim, S. Moutereau, T. Simon et al., “Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]),” The American Journal of Cardiology, vol. 111, pp. 31–37, 2013.

D. Perez-Sotelo, A. Roca-Rivada, M. Larrosa-Garcia et al., “Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity,” Endocrine, vol. 55, pp. 435–446, 2017.

J. M. Brix, H. Stingl, F. Hollerl, G. H. Schernthaner, H. P. Kopp, and G. Scherntahner, “Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss,” The Journal of Clinical Endocrinology and Metabolism, vol. 95, pp. 4877–4881, 2010.

M. Bluhner, A. Rudich, N. Kloting et al., “Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention,” Diabetes Care, vol. 35, pp. 342–349, 2012.

B. Schultes, J. Frick, B. Ernst, N. Stefan, and A. Frischke, “The effect of 6-weeks of aerobic exercise training on serum fetuin-A levels in non-diabetic obese women,” Experimental and Clinical Endocrinology & Diabetes, vol. 118, pp. 754–756, 2010.

S. K. Malin, J. P. del Rincon, H. Huang, and J. P. Kirwan, “Exercise-induced lowering of fetuin-A may increase hepatic insulin sensitivity,” Medicine and Science in Sports and Exercise, vol. 46, pp. 2085–2090, 2014.

A. Obuchi, H. Adachi, M. Enomoto et al., “High plasma fetuin-A levels are associated with metabolic syndrome among males but not females in a Japanese general population,” Diabetes Research and Clinical Practice, vol. 106, pp. 128–135, 2014.

A. S. Ryan, L. I. Katzel, S. J. Prior, J. C. McLennan, A. P. Goldberg, and H. K. Ortmyer, “Aerobic exercise plus weight loss improves insulin sensitivity and increases skeletal muscle glycogen synthase activity in older men,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 69, pp. 790–798, 2014.

S. J. Prior, A. S. Ryan, T. G. Stevenson, and A. P. Goldberg, “Metabolic inflexibility during submaximal aerobic exercise is associated with glucose intolerance in obese older adults,” Obesity (Silver Spring), vol. 22, pp. 451–457, 2014.

S. J. Prior, L. J. Joseph, J. Brandauer, L. I. Katzel, J. M. Hagberg, and A. S. Ryan, “Reduction in mid thigh low-density muscle with aerobic exercise training and weight loss impacts glucose tolerance in older men,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, pp. 880–886, 2007.

R. Andres, R. S. Sverdloff, T. Pozefsky, and D. Coleman, “Manual feedback technique for the control of blood glucose concentration,” in Automation in Analytical Chemistry (Technician Symposium), N. B. Scova, Ed., pp. 489–491, Mediad, New York, 1966.

R. A. DeFronzo, J. D. Tobin, and R. Andres, “Glucose clamp technique: a method for quantifying insulin secretion and resistance,” The American Journal of Physiology, vol. 237, pp. E214–E223, 1979.

S. J. Prior, J. B. Blumenthal, L. I. Katzel, A. P. Goldberg, and A. S. Ryan, “Increased skeletal muscle capillarization after aerobic exercise training and weight loss improves insulin sensitivity in adults with IGT,” Diabetes Care, vol. 37, pp. 1469–1475, 2014.

S. K. Malin, A. Mulya, C. E. Fealy et al., “Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease,” Journal of Applied Physiology, vol. 115, pp. 988–994, 2013.

H. Y. Ou, Y. C. Yang, H. T. Wu, J. S. Wu, F. H. Lu, and C. J. Chang, “Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, pp. 4717–4723, 2012.

N. Stefan, A. M. Hennige, H. Staiger et al., “Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans,” Diabetics Care, vol. 29, pp. 853–857, 2006.

S. Lee, F. Norheim, H. L. Gulseth et al., “Interaction between plasma fetuin-A and free fatty acids predicts changes in insulin sensitivity in response to long-term exercise,” Physiological Reports, vol. 5, 2017.

S. J. Yang, H. C. Hong, H. Y. Choi et al., “Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women,” Clinical Endocrinology, vol. 75, pp. 464–469, 2011.

M. K. Jensen, T. M. Bartz, L. Djoussé et al., “Genetically elevated fetuin-A levels, fasting glucose levels, and risk of type 2 diabetes: the cardiovascular health study,” Diabetes Care, vol. 36, pp. 3121–3127, 2013.

M. Emoto, K. Mori, E. Lee et al., “Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus,” Metabolism, vol. 59, pp. 873–878, 2010.

K. Mori, Y. Ikari, S. Jono et al., “Fetuin-A is associated with calcified coronary artery disease,” Coronary Artery Disease, vol. 21, pp. 281–283, 2010.

A. Heiss, T. Eckert, A. Aretz et al., “Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles,” The Journal of Biological Chemistry, vol. 283, pp. 14815–14825, 2008.

L. Yin, W. J. Cai, X. Y. Chang et al., “Association between fetuin-A levels with insulin resistance and carotid intima-media thickness in patients with new-onset type 2 diabetes mellitus,” Biomedical Reports, vol. 2, pp. 839–842, 2014.

J. H. Ix, R. Katz, I. H. de Boer et al., “Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis,” Clinical Chemistry, vol. 58, pp. 887–895, 2012.

Z. Szebérin, M. Fehervari, M. Krepsuca et al., “Serum fetuin-A levels inversely correlate with the severity of arterial calcification in patients with chronic lower extremity atherosclerosis without renal disease,” International Angiology, vol. 30, pp. 474–450, 2011.

J. H. Ix, E. Barrett-Connor, C. L. Wassel et al., “The associations of fetuin-A with subclinical cardiovascular disease in...
community-dwelling persons: the Rancho Bernardo Study,”
Journal of the American College of Cardiology, vol. 58,
pp. 2372–2379, 2011.

[36] G. A. Laughlin, K. M. Cummins, C. L. Wassel, L. B. Daniels,
and J. H. Ix, “The association of fetuin-A with cardiovascular
disease mortality in older community-dwelling adults: the
Rancho Bernardo study,” Journal of the American College of
Cardiology, vol. 59, pp. 1688–1696, 2012.

[37] Z. L. Sun, Q. Y. Xie, G. L. Guo, K. Ma, and Y. Y. Huang,
“Serum fetuin-A levels in patients with cardiovascular disease:
a meta-analysis,” BioMed Research International, vol. 2014,
Article ID 691540, 9 pages, 2014.

[38] K. R. Wilund, E. J. Tomayko, E. M. Evans, K. Kim, M. R.
Ishaque, and B. Fernhall, “Physical activity, coronary artery
calcium, and bone mineral density in elderly men and
women: a preliminary investigation,” Metabolism, vol. 57,
pp. 584–591, 2008.